Currently, there are scarce data on how COVID-19 affects people with myasthenia gravis. Theoretically, there is a higher risk of experiencing severe manifestations of COVID-19 due to the common use of immunosuppressive drugs and potential respiratory failure in relation to respiratory muscle weakness. This is one of the early cases of COVID-19 reported in association with myasthenia gravis. Here, we highlight the prognosis, discuss the pathophysiological mechanisms, and prompt the consideration of convalescent plasma therapy in myasthenia gravis patients with concomitant COVID-19.
All Keywords
【초록키워드】 COVID-19, Respiratory failure, Prognosis, Convalescent plasma therapy, Patient, association, manifestation, higher risk, weakness, pathophysiological mechanisms, Affect, highlight, reported, immunosuppressive drug, 【제목키워드】 COVID-19, review, literature, Myasthenia, report, presentation,
【초록키워드】 COVID-19, Respiratory failure, Prognosis, Convalescent plasma therapy, Patient, association, manifestation, higher risk, weakness, pathophysiological mechanisms, Affect, highlight, reported, immunosuppressive drug, 【제목키워드】 COVID-19, review, literature, Myasthenia, report, presentation,